Phase II SCLC Study
An open-label, phase II study of the polo-like kinase-1 (Plk-1) inhibitor, BI 2536, in patients with relapsed small cell lung cancer (SCLC). Awad MM, Chu… Phase II SCLC Study
News & Events
The DART Study
The DART Study: Results from the Dose-Escalation and Expansion Cohorts Evaluating the Combination of Dalantercept plus Axitinib in Advanced Renal Cell Carcinoma. Voss MH, Bhatt… The DART Study
Prevention of everolimus-related stomatitis
Prevention of everolimus-related stomatitis in women with hormone receptor-positive, HER2-negative metastatic breast cancer using dexamethasone mouthwash (SWISH): a single-arm, phase 2 trial. Rugo HS, Seneviratne… Prevention of everolimus-related stomatitis
Managing Expectations in the Transition to Proof of Concept Studies
Managing Expectations in the Transition to Proof of Concept Studies. Kieber-Emmons T, Makhoul I, Pennisi A, Siegel ER, Emanuel PD, Monzavi-Karbassi B, Steplewski Z, Beck… Managing Expectations in the Transition to Proof of Concept Studies
The Role of Proteomic Testing in Improving Prognosis And Care Planning Quality Measures for Lung Cancer
The Role of Proteomic Testing in Improving Prognosis And Care Planning Quality Measures for Lung Cancer. Page RD, Argento AC, Nash DB, Skoufalos A, Schaefer… The Role of Proteomic Testing in Improving Prognosis And Care Planning Quality Measures for Lung Cancer
Longitudinal quality of life while on chemotherapy
nab-paclitaxel/carboplatin induction in squamous NSCLC: longitudinal quality of life while on chemotherapy. Thomas M, Spigel DR, Jotte RM, McCleod M, Socinski MA, Page RD, Gressot… Longitudinal quality of life while on chemotherapy
Measuring Quality Is Complicated
Measuring Quality Is Complicated Patt D, Page R. J Oncol Pract. 2017 Dec 6:JOP2017027789. doi: 10.1200/JOP.2017.027789. [Epub ahead of print] No abstract available. PMID: 29211577
Financial Conflicts of Interest Among Oncology Clinical Pathway Vendors
Financial Conflicts of Interest Among Oncology Clinical Pathway Vendors Daly B, Bach PB, Page RD. JAMA Oncol. 2017 Dec 21. doi: 10.1001/jamaoncol.2017.4473. [Epub ahead of… Financial Conflicts of Interest Among Oncology Clinical Pathway Vendors
Ipatasertib plus paclitaxel versus placebo plus paclitaxel as first-line therapy for metastatic triple-negative breast cancer (LOTUS)
Ipatasertib plus paclitaxel versus placebo plus paclitaxel as first-line therapy for metastatic triple-negative breast cancer (LOTUS): a multicentre, randomised, double-blind, placebo-controlled, phase 2 trial. BACKGROUND:The… Ipatasertib plus paclitaxel versus placebo plus paclitaxel as first-line therapy for metastatic triple-negative breast cancer (LOTUS)
Impact of a multivariate serum-based proteomic test on physician treatment recommendations for advanced non-small-cell lung cancer.
The VeriStrat 1 (VS) test is intended to help guide treatment decisions for patients with advanced non-small-cell lung cancer (NSCLC) without an EGFR-sensitizing mutation, classifying… Impact of a multivariate serum-based proteomic test on physician treatment recommendations for advanced non-small-cell lung cancer.